Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Combined lapatinib and paclitaxel in HER2-positive breast cancer

A randomized phase III trial evaluated the effect of adding lapatinib to paclitaxel as first-line therapy for patients with metastatic breast cancer whose tumors were negative or untested for human epidermal growth factor receptor 2 (HER2) overexpression. Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).

    Article  Google Scholar 

  2. Johnston, J. B. et al. Targeting the EGFR Pathway for Cancer Therapy. Curr. Medicinal Chem. 13, 3483–3492 (2006).

    Article  CAS  Google Scholar 

  3. Jin, Q. & Esteva, F. J. Cross-talk between the ErbB/HER Family and the type I Insulin- like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 485–498 (2008).

    Google Scholar 

  4. Gomez, H. L. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999–3005 (2008).

    Article  CAS  Google Scholar 

  5. Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 10, 1007 (2008).

    Google Scholar 

  6. Herendeen, J. M. et al. An open label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine [Abstract]. ASCO Meeting Abstracts 22, 3081 (2004).

    Google Scholar 

  7. Beulz-Riche, D., Robert, J., Riché, C. & Ratanasavanh, D. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother. Pharmacol. 49, 274–280 (2002).

    Article  CAS  Google Scholar 

  8. Jones, S. F. et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [Abstract]. ASCO Meeting Abstracts 22, 2083 (2004).

    Google Scholar 

  9. Cristofanilli, M. et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [Abstract]. San Antonio Breast Cancer Symposium, 2006 December 14–17, San Antonio, TX.

    Google Scholar 

  10. Di Leo, A. et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544–5552 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Henry L. Gomez.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castañeda, C., Gomez, H. Combined lapatinib and paclitaxel in HER2-positive breast cancer. Nat Rev Clin Oncol 6, 308–309 (2009). https://doi.org/10.1038/nrclinonc.2009.68

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.68

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing